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Association of past dengue fever 
epidemics with the risk of Zika 
microcephaly at the population 
level in Brazil
Marilia Sá carvalho  1*, Laís picinini freitas  2, oswaldo Gonçalves cruz1, patrícia Brasil3 & 
Leonardo Soares Bastos  1
Despite all the research done on the first Zika virus (ZIKV) epidemics, it was only after the Brazilian 
epidemic that the congenital Zika Syndrome was described. this was made possible due to the 
large number of babies born with microcephaly in the Northeast region (NE) in a narrow time. We 
hypothesize that the fivefold difference in the rate of microcephalic neonates between the NE and 
other regions is partially an effect of the population prior immunity against Dengue viruses (DENV), 
that cross-react with ZIKV. In this ecological study, we analysed the interaction between dengue fever 
epidemics from 2001 to 2014 and the 2015/2016 microcephaly epidemic in 400 microregions in Brazil 
using random-effects models under a Bayesian approach. The estimated effect of the time lag between 
the most recent large dengue epidemic (>400/100,000 inhabitants) and the microcephaly epidemic 
ranged from protection (up to 6 years prior) to an increased risk (from 7 to 12 years). This sustained 
window of protection, larger than described in previous longitudinal studies, is possibly an effect of herd 
immunity and of multiple exposures to DENV that could boost immunity.
One of the reasons that made it possible for researchers to associate the microcephaly epidemic in the Northeast 
(NE) region of Brazil with the Zika virus (ZIKV) was the high rate of dispersion of the virus and the large num-
ber of babies born with similar characteristics in the same maternity wards, in the same week, and sometimes 
even in the same day. This repeatedly happened in different cities of the region in a short time1. Despite all the 
research done on the first epidemics of ZIKV in Yap Islands and later in French Polynesia2–4, it was only after the 
Brazilian epidemic that Congenital Zika Syndrome (CZS) was described5. This could be due to the small popu-
lation in the previously affected areas and to the large number of births concentrated in the same hospitals of the 
Brazilian Unified Health System (SUS). Even so, a robust analysis using secondary databases estimated a peak of 
49.9 microcephaly cases per 10,000 live births in the NE region, whereas for the other regions the peak did not 
surpass 10 cases per 10,000 live births6. So far, microcephaly ratios as high as in the Brazilian NE region have not 
been described in any other region in the world that had undergone a Zika epidemic7–9. Several reasons for this 
discrepancy were suggested – poor data quality10–12, the unreliability of secondary data sources13,14, virus genetic 
variation15, socioeconomic factors16, dengue immunity profile of the population17, and women postponing preg-
nancy or having abortions18–20.
The antigenic similarity between ZIKV and dengue virus (DENV), sharing approximately 54% of their amino 
acid envelope proteins, results in immunological cross-reactivity21. In vitro studies have shown that anti-DENV 
antibodies can both enhance and neutralize ZIKV infection22–26. In animal models, mice that received plasma 
with a low level of anti-DENV antibodies had a higher mortality rate after ZIKV infection than mice that 
received plasma without antibodies. However, all mice that received plasma with a high level of anti-DENV 
antibodies survived after ZIKV challenge and presented milder symptoms22. Human plasma collected ≤100 
days after PCR-confirmed DENV infection binds and cross-neutralizes ZIKV in vitro. On the other hand, 
late-convalescent-phase plasma does not harbour durable, high levels of cross-neutralizing antibodies against 
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ZIKV27. However, the understanding of cross-neutralizing antibody responses among individuals with prior 
DENV exposure, particularly how these responses evolve over time and in various transmission contexts in 
flavivirus-endemic countries is quite unknown28.
In summary, it is known that ZIKV shares structural similarities with other flaviviruses, especially DENV, and 
co-circulates in dengue-endemic regions. ZIKV and DENV cross-immunity can be either protective or enhanc-
ing in experimental models. However, many questions still need to be addressed, particularly by placing in vitro 
and in vivo findings in an epidemiological context29,30. In this article, we analyse the interaction between dengue 
fever epidemics from 2001 to 2014 and the 2015/2016 microcephaly epidemic in 400 microregions in Brazil.
Methods
Data. This is an ecological study using data gathered by the Health Informatics Department of the Brazilian 
Ministry of Health (DATASUS). All data are publicly available at the DATASUS website (http://www.datasus.gov.
br/DATASUS/index.php/index.php?area=02).
The neonates’ data are collected by the Brazilian Live Births Information System (SINASC), which includes 
a field to inform the presence of an observed malformation and five fields to classify the condition. Since, at the 
time, CZS did not have a specific code, we considered as a microcephaly case a live-born with the microcephaly 
code “Q02” (10th edition of the ICD) in any of the five fields. We compared the number of microcephaly cases 
between 2015–2016, considered the epidemic period, to the 2014 data, both in the exploratory analysis and the 
maps.
Dengue data are collected by the Brazilian Information System for Notifiable Diseases (SINAN). We obtained 
the number of dengue fever cases by municipality and epidemiological week from 2001 to 2014. For the same 
period, annual population data by municipality estimated by the Brazilian Institute of Geography and Statistics 
(IBGE), the census bureau, were also obtained.
We excluded the North region (where the Amazon forest is located) due to poorer data quality and incomplete 
birth records, and the South region, not endemic for dengue fever or any arboviral disease.
Maps were made using QGIS (version 3.6.3)31 and layers from IBGE (available at https://downloads.ibge.gov.
br/downloads_geociencias.htm), and terrain background by Stamen Design (data by OpenStreetMap).
In accordance with the Brazilian Research Ethics, ethical approval is not mandatory for the use of publicly 
available datasets.
exploratory analysis. Live-born data was aggregated by 400 socioeconomically homogeneous microre-
gions, as defined by the census bureau. As dengue fever counts are organized by epidemiological week, the 
first approach was to use this time scale (Fig. 1a,b). Maps (Fig. 2a,b) present the overall microcephaly rate per 
10,000 live-born babies and dengue fever incidence per 100,000 inhabitants by microregion in the three selected 
Brazilian macroregions: NE, Central-West (CW) and Southeast (SE).
Models. Using the microcephaly counts as the dependent variable and the total number of live births as offset, 
we fitted four random-effects models varying the likelihood: Poisson, Negative Binomial, zero-inflated Poisson 
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Figure 1. Microcephaly and dengue fever indicators per week per macroregion, Brazil. Frame (a) presents the 
rate of microcephaly cases per 10,000 live-births by week in each region analysed, and frame (b) depicts the 
dengue fever incidence rate per 100,000 inhabitants, in the same time scale.
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and zero-inflated Negative Binomial. Two random-effects components were included in the model: the first is a 
time-varying coefficient for the time since the last big dengue epidemic modelled as a second-order random walk 
to allow a smooth non-linear behaviour. The second random-effects component was an independent and iden-
tically distributed Gaussian random effect by microregion. Vague priors were used and the inference was done 
under the Bayesian approach using the integrated nested Laplace approximation (INLA)32.
To evaluate the time lag between the microcephaly epidemic and a previous dengue fever epidemic, we 
assessed several rate thresholds (100, 200, 300, 400, 500, and 600 cases per 100,000 inhabitants) and statisti-
cal distributions (Supplemental Material). The best fit, according to the Watanabe-Akaike information criterion 
(WAIC)33, was obtained with the zero-inflated Poisson model and 400 cases per 100,000 inhabitants as the thresh-
old of a dengue epidemic.
In brief, the model evaluates the number of microcephaly cases, considering the total number of live births as 
offset, and dengue fever epidemics with an incidence above 400/100,000 between one and fourteen years prior 
as an explanatory variable. The model included two random effects: (1) microregion random effects consid-
ering both a spatial structured random effect and an unstructured one, allowing for spatial dependence and 
extra-variability, and (2) spline-like random effects for the time, in years, since the last dengue epidemic in each 
region.
We used the R software34 with the tidyverse library35 to organize the data and present the results, and R-INLA36 
for the analysis. The R code is available in the Supplemental Material.
Results
The total number of microcephaly cases increased more than 23-fold between 2014 and 2015 in the NE region, 
and more than tenfold in both the SE and CW regions between 2015 and 2016 (Table 1). The number of live births 
in 2016 decreased 5% in the NE and CW regions, and 6% in the SE, compared with 2015, following the declara-
tion of public health emergency by the Brazilian Health authorities. In just one week, the number of microcephaly 
cases in 2015 in the NE region reached 29, more than half of the total number of microcephaly cases from the 
Figure 2. Rate of microcephaly cases per 10,000 live-born infants per microregion, Brazil, 2014. Map created 
using QGIS version 3.6.3 (QGIS Development Team 2019. QGIS Geographic Information System. Open Source 
Geospatial Foundation Project. http://qgis.osgeo.org). Map tiles by Stamen Design, under CC BY 3.0. (https://
creativecommons.org/licenses/by/3.0/) Data by OpenStreetMap, under CC BY SA.
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previous year. The number of microregions with no microcephaly cases decreased first in the NE, the dispersion 
centre of Zika epidemic, followed by the SE and CW regions.
The rate of microcephaly in neonates per 10,000 live births per week by Brazilian macroregions is presented 
in Fig. 1a. The increase of microcephaly rate beginning at the end of 2015 is observed in all regions. However, in 
the NE region, by August/2015 the rate had surpassed 30 cases per 10,000 live births, while in other regions it was 
never higher than 20/10,000 live births. In the SE and CW regions, a second peak occurred at the end of 2016. 
Comparing the incidence rates of dengue fever (Fig. 1b) in the SE and CW regions, three epidemic years (2010, 
2013 and 2015) are present, while in the NE region, in the same period, we observed just a seasonal pattern with 
no outbreaks.
The map presented in Fig. 2 shows the usual pattern of microcephaly rate among live-born neonates in 2014, 
before the Zika epidemic. Among the 400 microregions included in the analysis, in 318 (80%) no microcephalic 
neonate was reported, and the highest rate was due to two babies born in an area with a small population.
The microcephaly epidemic data map (Fig. 3) depicted a different pattern: more than 60% of the areas in the 
SE and CW regions did not present any cases, while in the NE this proportion was just 20% (Table 1).
Figure 4 depicts the mean dengue fever incidence rate over five years (2010–2014). The spatial pattern, as com-
pared with Fig. 3, is inverted: in areas with high microcephaly rates, dengue fever incidence rates were smaller.
To estimate the association between both indicators – microcephaly rate and previous dengue fever incidence 
– we estimated the effect of the time lag between the most recent large dengue epidemic and the microcephaly 
epidemic. Figure 5 presents the main results of this article: the credibility time interval since the last dengue fever 
epidemic above 400 cases/100,000 inhabitants over the rate of microcephalic neonates. This finding suggests a 
protective effect up to 6 years prior to an increased risk from 7 to 12 years.
The random effect estimated for each microregion, as presented in Fig. 6, suggests that the dengue fever epi-
demic effect is not enough to explain the large number of microcephaly cases in some areas in the NE. The 
Supplemental material presents the results of different models, exploring dengue epidemic definitions from 100 to 
600/100,000 inhabitants and other statistical distributions. Blue areas are those with a lower rate of microcephaly 
cases than predicted by the time lag after the last dengue fever epidemic, while orange/red areas are the opposite. 
In some areas, the estimated random effect is above two standard deviations, mostly spatially concentrated in the 
NE region.
Discussion
This is the first article, to the best of our knowledge, in which an association, at the ecological level, between pre-
vious dengue fever epidemics and the Zika-related microcephaly epidemic was described. It should be noted that 
the notification system for Zika was only implemented in February 2016, when the Zika epidemic was decreasing 
in the NE region. Therefore, we could not control for Zika incidence in the models. It is possible that the differ-
ences in microcephaly rates were a consequence of different ZIKV attack rates across the regions, as suggested in 
a recent paper37. In this study, after testing for other concurrent factors, ZIKV was assumed to be the only cause 
of the microcephaly epidemic, with no unmeasured confounders or effect modifiers. However, if Zika incidence 
alone explains the excess microcephaly rates, then microcephaly would simply be a proxy for Zika, and it remains 
unclear as to why the NE region would have presented with a Zika incidence more than ten times larger than 
anywhere else in Brazil37.
Our hypothesis considers that the antibody decay due to the time interval between infections changes 
the role of anti-DENV antibodies on ZIKV infection, either to protect or to increase the risk (possibly via 
antibody-dependent enhancement – ADE), as illustrated in Fig. 7. This hypothesis is based on what is described 
for sequential heterotypic DENV infections (there are four DENV serotypes). It has been established that a 
narrow range of pre-existing anti-DENV antibody titres is associated with the risk of severe dengue disease, 
while high titres protect against clinical illness29,38. As the antibody titres decay over time, there is a window of 
cross-protection between the DENV serotypes. A previous study found that a shorter interval between first and 
Year Northeast Southeast Central-West
Microcephaly cases
2014 55 76 12
2015 1294 283 62
2016 1071 844 138
Live births
2014 838094 1189848 246450
2015 844590 1193720 247069
2016 799760 1123013 233888
Maximum number of microcephaly cases in 
one week
2014 2 2 1
2015 29 15 5
2016 19 10 3
Percentage of microregions with zero 
microcephaly cases
2014 79.3% 78.8% 82.7%
2015 22.3% 61.3% 69.2%
2016 19.7% 37.5% 37.7%
Table 1. Number of microcephaly cases in neonates, number of live births, the maximum number of 
microcephaly cases in one week, and proportion of microregions with zero microcephaly cases, by year and 
macroregion, Brazil.
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second infections was associated with protection from clinical illness39. Additionally to antibodies, DENV-specific 
CD8+ T cells from previous exposure also seems to play a role against ZIKV. Mice primed with DENV and 30 
days later challenged with ZIKV during pregnancy presented reduced burden in maternal and fetal tissues, and 
increased fetal viability compared to non-immune mice. DENV-immune CD8+ T cells were required for this 
cross-protection. However, mice challenged 80 days after DENV priming were not protected, indicating the tran-
sient nature of cross-protection again40.
Most research on the effect of previous DENV-immunity on the severity of clinical symptoms of ZIKV infec-
tion is based on experimental models41,42. Cohort studies are the golden standard to epidemiological designs 
to estimate disease incidence and would give the most reliable understanding of the role of previous DENV 
exposure on ZIKV infection. However, the reduction in the incidence of Zika after the last epidemic in Brazil in 
2016 limits the ability to use prospective studies43–45. Some cohorts previously designed to study dengue and that 
have been adapted to also study Zika are of great value. For example, a recent study in the Pau da Lima cohort in 
Salvador, a large city of the NE region, Brazil, found that the titres of DENV-antibodies measured before the Zika 
epidemic were inversely associated with the risk of ZIKV infection46. In a paediatric cohort in Nicaragua, prior 
DENV infection was inversely associated with the risk of symptomatic ZIKV infection47.
In a cohort of ZIKV-infected pregnant women, previous DENV infection was not associated with disease 
severity and abnormal birth outcomes48. However, the time interval between the infections and the anti-DENV 
antibody titres were not considered in the analysis. Our findings indicate that a previous dengue fever epidemic 
may be related to microcephaly incidence and reinforce the idea of a window of cross-protection and a window 
of increased risk. Our window of protection is wider than detected in a longitudinal analysis of human immune 
sera, which showed a cross-neutralizing antibody response to ZIKV on DENV-immune subjects 1–3 years after 
DENV infection28. The larger window at the ecological level is possibly an effect of herd immunity and of multiple 
exposures to DENV that would boost immunity. This is consistent with a case-control study in which the DENV 
seroprevalence and the mean number of neutralized serotypes (indicative of multiple exposures) were signifi-
cantly lower among mothers of neonates with CZS49.
Figure 3. Rate of microcephaly cases per 10,000 live-born infants per microregion, Brazil, 2015–2016. Map 
created using QGIS version 3.6.3 (QGIS Development Team, 2019, QGIS Geographic Information System. 
Open Source Geospatial Foundation Project. http://qgis.osgeo.org). Map tiles by Stamen Design, under CC BY 
3.0. (https://creativecommons.org/licenses/by/3.0/) Data by OpenStreetMap, under CC BY SA.
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Figure 4. Average annual dengue fever incidence rate per 100,000 over 2010–2014 by microregion, Brazil. Map 
created using QGIS version 3.6.3 (QGIS Development Team, 2019. QGIS Geographic Information System. 
Open Source Geospatial Foundation Project. http://qgis.osgeo.org). Map tiles by Stamen Design, under CC BY 
3.0. (https://creativecommons.org/licenses/by/3.0/) Data by OpenStreetMap, under CC BY SA.
Figure 5. Estimated microcephaly risk (log) and credibility interval by number of years since the last dengue 
fever epidemic (incidence >400/100,000).
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We applied a powerful modelling strategy using the INLA approach32, which allowed us to simultaneously 
take into account the non-linear behaviour of the time since the last dengue epidemic (Fig. 5) and the excess 
variation in each area, as discussed above and shown in Fig. 6. The 18 areas highlighted with higher risks than 
predicted by the model should be further investigated.
In the easternmost area of the NE region there was an excess of two standard deviations over the number of 
microcephalic neonates predicted by the model (Fig. 6). In this area, the involvement among researchers and 
clinicians that led to the early discovery of the causal link between Zika and microcephaly may have generated a 
hyper-awareness of the problem. The more strict head circumference measurements counterbalanced the usual 
under-reporting11,50. It should be noted that the main surveillance system for neonatal congenital malformation 
(Latin American Collaborative Study of Congenital Malformations – ECLAMC) did not detect the microceph-
aly epidemic in the early stages14, possibly due to the geographical constraints of the sentinel hospitals. The use 
Figure 6. Microregion random effects estimated by the fitted model, presented in standard deviation units. 
Map created using QGIS version 3.6.3 (QGIS Development Team, 2019. QGIS Geographic Information System. 
Open Source Geospatial Foundation Project. http://qgis.osgeo.org). Map tiles by Stamen Design, under CC BY 
3.0. (https://creativecommons.org/licenses/by/3.0/) Data by OpenStreetMap, under CC BY SA.
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Figure 7. Hypothesized interaction between dengue and Zika infections on the development of microcephaly.
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of a secondary database such as SINASC, despite its accuracy limitations, together with the more specialized 
ECLAMC could reinforce a surveillance system for neonatal malformation clustered in space and time.
Dengue epidemics in the previous 15 years were used as a proxy of the herd immunity level among women 
of reproductive age. The choice of the threshold that we considered high enough to either protect or increase 
microcephaly risk (of 400/100,000 inhabitants) was data-driven, based on the best fit. The threshold of 300 
cases/100,000 inhabitants as high incidence areas, as defined by the Brazilian Ministry of Health, is a number 
defined ad hoc, not sustained by any scientific argument in any guideline of the dengue control program pub-
lished since 2002.
Other possible factors in the pathway between Zika infection and microcephaly have been suggested, the 
most important of which is the socioeconomic deprivation in the Brazilian NE16,51. This is a typical confounding 
problem, not easily addressed, mainly due to the larger reservoirs of Aedes aegypti in poor areas and increased 
awareness of the microcephaly risk in the upper socioeconomic classes, inducing either postponing pregnancy 
during epidemic periods or voluntary abortion, not legal in Brazil52.
The main limitations of this study, in addition to not controlling for Zika incidence, are well known: accu-
racy of microcephaly classification and completeness of dengue fever notification. We recognize the potential 
inaccuracy on the measurement of neonates’ cephalic perimeter. Considering 10% fewer neonates classified as 
microcephalic in the NE and 10% more in other regions, the difference would be fourfold, instead of five. As for 
the under notification of dengue fever, we have no reason to believe there was a trend over the years that would 
affect our results.
The detection of either ADE or cross-protection between DENV and ZIKV is not a trivial task, either in ani-
mal models or humans42. The increase in congenital malformations is not easily studied, considering a confluence 
of different risk factors and the large range of time lags between the potentially harmful event and the outcome. 
We believe that we brought new evidence that will contribute to building the knowledge regarding the relation-
ship between DENV, ZIKV and congenital Zika syndrome.
Data availability
The original datasets are publicly available at http://datasus.saude.gov.br, and the data organised for the present 
analysis at https://doi.org/10.5281/zenodo.3489428.
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